BofA initiated coverage of Supernus (SUPN) with a Buy rating and $65 price target citing what it sees as the “underappreciated” branded central nervous system growth drivers with its treatments for ADHD and motor complications in advanced Parkinson’s disease. Qelbree offers a differentiated non-stimulant that continues to capture share both from patients new to treatment and those switching from other therapies, while Onapgo has “impressed” in its first quarter on the market, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus Pharmaceuticals’ Real-World Study on ONAPGOTM: A Closer Look
- Supernus Pharmaceuticals Advances ADHD Treatment Study in Young Children
- Supernus Pharmaceuticals Advances SPN-817 Study for Seizure Treatment
- Supernus Pharmaceuticals Advances with RENAISSANCE 2 Study on SPN-817
- Supernus price target raised to $60 from $45 at TD Cowen